FCF Yield

The current FCF Yield of 2.3% means Bio-Techne generates $2.30 in free cash flow for every $100 of its market value — a measure of how much cash the business can return to shareholders relative to its stock price.

This sits below the healthcare sector median of 3.4%, placing the company in the 32nd percentile among its peers, indicating weaker cash return efficiency. The year-over-year change is not available, but the quarter-over-quarter change shows a decline of 20.7%, and the only historical values given are 2.9% followed by the current 2.3%, pointing to a downward move. The combination of a below-median level and a falling trend implies increased risk for income-focused investors, as the company’s ability to generate cash relative to its valuation is deteriorating. This metric directly supports the NEUTRAL verdict: the low and shrinking FCF Yield does not argue for a bullish stance, but the absence of a multi-quarter trend and a single sequential drop do not confirm a strong negative either, consistent with a neutral assessment.

Frequently Asked Questions

Closest Sector Peers